Dare Bioscience Stock Analysis

Dare Stock Analysis Notes

The company recorded a loss per share of 1.83. Dare Bioscience last dividend was issued on the 20th of July 2017. The entity had 1:12 split on the 1st of July 2024. Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for womens health in the United States. Dar Bioscience, Inc. is headquartered in San Diego, California. Dare Bioscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To learn more about Dare Bioscience call Sabrina Johnson at 858 926 7655 or check out https://darebioscience.com.

Dare Bioscience Investment Alerts

Dare Largest EPS Surprises

View All Earnings Estimates

Dare Stock Institutional Investors

Note, although Dare Bioscience's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dare Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.92 M.

Dare Profitablity

Management Efficiency

Dare Bioscience has return on total asset (ROA) of (0.4474) % which means that it has lost $0.4474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (25.4313) %, meaning that it created substantial loss on money invested by shareholders. Dare Bioscience's management efficiency ratios could be used to measure how well Dare Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.64, whereas Return On Tangible Assets are projected to grow to (0.17). At present, Dare Bioscience's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.3 M, whereas Other Assets are forecasted to decline to 0.86.

Technical Drivers

As of the 16th of February 2026, Dare Bioscience shows the Standard Deviation of 4.19, mean deviation of 2.98, and Variance of 17.55. Dare Bioscience technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Dare Bioscience information ratio, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Dare Bioscience is priced favorably, providing market reflects its regular price of 1.71 per share. Please also check Dare Bioscience jensen alpha, which is currently at (0.1) to verify the company can sustain itself at a future point.

Dare Bioscience Price Movement Analysis

Dare Bioscience Insider Trading Activities

Dare Bioscience Outstanding Bonds

Dare Bioscience Predictive Daily Indicators

Dare Bioscience Forecast Models

Dare Bioscience's time-series forecasting models are one of many Dare Bioscience's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dare Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Dare Bioscience Bond Ratings

Dare Bioscience financial ratings play a critical role in determining how much Dare Bioscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Dare Bioscience's borrowing costs.

Dare Bioscience Debt to Cash Allocation

Dare Bioscience currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Dare Bioscience has a current ratio of 2.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dare Bioscience's use of debt, we should always consider it together with its cash and equity.

Dare Bioscience Total Assets Over Time

Dare Bioscience Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Dare Bioscience uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Dare Bioscience Debt Ratio

6.44

It looks as if most of the Dare Bioscience's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Dare Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Dare Bioscience, which in turn will lower the firm's financial flexibility.

Dare Bioscience Corporate Bonds Issued

Dare Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dare Bioscience prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dare shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dare Bioscience. By using and applying Dare Stock analysis, traders can create a robust methodology for identifying Dare entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dare analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dare analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Dare Bioscience stock analysis indicators help investors evaluate how Dare Bioscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dare Bioscience shares will generate the highest return on investment. By understating and applying Dare Bioscience stock analysis, traders can identify Dare Bioscience position entry and exit signals to maximize returns.

When running Dare Bioscience's price analysis, check to measure Dare Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dare Bioscience is operating at the current time. Most of Dare Bioscience's value examination focuses on studying past and present price action to predict the probability of Dare Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dare Bioscience's price. Additionally, you may evaluate how the addition of Dare Bioscience to your portfolios can decrease your overall portfolio volatility.